维格列汀联合曲美他嗪对糖尿病合并心衰大鼠心功能影响的分析  

Effect of Vildagliptin Combined with Trimetazidine on Cardiac Function in Rats with Diabetes Mellitus Complicated with Heart Failure

作　　者：吴翔[1] 王世祥[2] 张晶晶[3] 乔建峰[1] 熊尚全[1] WU Xiang;WANG Shi-xiang;ZHANG Jing-jing;QIAO Jian-feng;XIONG Shang-quan(Department of Cardiology, People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian Province, 350004 China;Department of Cardiology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province, 510150 China;Department of Pharmacy, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510280 China)

机构地区：[1]福建中医药大学附属人民医院心血管科,福建福州350004 [2]广州医科大学附属第三医院心血管内科,广东广州510150 [3]南方医科大学珠江医院药剂科,广东广州510280

出　　处：《糖尿病新世界》2018年第24期6-8,共3页Diabetes New World Magazine

摘　　要：目的探讨维格列汀联合曲美他嗪对糖尿病合并心衰大鼠对心功能影响。方法选取60只SD大鼠,建立糖尿病合并心衰模型,随机分为糖尿病合并心衰组(A组)、糖尿病合并心衰加曲美他嗪组(B组)、糖尿病合并心衰加曲美他嗪联合维格列汀组(C组),各20只,在治疗前及给药6周后检测3组大鼠心功能指标,并检测空腹血糖、脑钠肽(NT-proBNP)。结果治疗前,3组大鼠心功能指标对比差异无统计学意义(P>0.05),治疗后3组大鼠的LVEDP、LVSP、-dp/dt max、+dp/dt max对比存在明显差异,C组与B大鼠LVEDP明显低于治疗前及治疗后A组,LVSP、-dp/dt max、+dp/dt max明显高于治疗前及治疗后A组(P<0.05),且C组大鼠各指标变化程度较B组更显著(P<0.05),A组大鼠心功能指标治疗前后差异无统计学意义(P>0.05);治疗前,3组大鼠空腹血糖及NT-NT-proBNP水平对比差异无统计学意义(P>0.05),治疗后,3组空腹血糖均较治疗前明显降低(P<0.05),但3组之间对比差异无统计学意义(P>0.05),3组大鼠之间NT-NT-proBNP水平之间差异有统计学意义(P<0.05),其中C组与B组大鼠NT-NT-proBNP水平明显低于治疗前及治疗后A组,且C组降低程度较B组更显著(P<0.05)。结论维格列汀联合曲美他嗪治疗糖尿病合并心衰大鼠可有效改善心功能。Objective To investigate the effect of vildagliptin combined with trimetazidine on cardiac function in rats with diabetes mellitus complicated with heart failure. Methods 60 SD rats were randomly divided into two groups: diabetic patients with heart failure (group A), diabetes with heart failure plus trimetazidine (group B), diabetes with heart failure plus melody histazine combined with vildagliptin (group C), 20 rats each, were tested for cardiac function in three groups before treatment and 6 weeks after administration, and fasting blood glucose and brain natriuretic peptide (NT-proBNP) were detected. Results Before treatment, there was no significant difference in cardiac function between the three groups (P>0.05).There were significant differences in LVEDP, LVSP,-dp/dt max and +dp/dt max between the three groups after treatment.Group C Compared with group B before and after treatment, LVSP,-dp/dt max,+dp/dt max were significantly higher than those in group A (P<0.05), and group C of the degree of change of each index was more significant than that of group B (P<0.05). There was no significant difference between the group A of rats in the heart function index before and after treatment (P >0.05). Before treatment, the levels of fasting blood glucose and NT-NT-proBNP in the three groups were compared.There was no significant difference (P>0.05). After treatment, the fasting blood glucose of the three groups was significantly lower than that before treatment (P<0.05), but there was not statistically significant difference between the three groups (P>0.05). There was a significant difference between NT-proBNP levels of the three groups (P<0.05). The levels of NT-NTproBNP in group C and group B were significantly lower than those in group A before and after treatment, and the degree of reduction in group C was more than that in group B (P<0.05). Conclusion Viglietin combined with trimetazidine in the treatment of diabetic rats with heart failure can effectively improve cardiac function.

关 键 词：糖尿病 心力衰竭 维格列汀 曲美他嗪 

分 类 号：R541.6[医药卫生—心血管疾病]